Articles Referencing RGEN
Isis Pharma's ISIS-SMNRx Progresses - Analyst Blog
4/24/2013, 5:09 pm from Zacks.com in Investing, Business, Stocks
Isis Pharmaceuticals, Inc. ( ISIS ) recently
commenced a phase II study with its spinal muscular atrophy (SMA)
candidate, ISIS-SMNRx. The open-label, multiple-dose, dose-escalation pilot... Read >>
Repligen Promises To Be A Cash Flow Machine
4/2/2013, 3:59 pm from SeekingAlpha in Investing, Stocks
By Smith On Stocks : Investment Overview Repligen ( RGEN
) has gone through a metamorphosis that has dramatically changed
its business model and investment outlook. For many years,... Read >>
Positive Results on MDCO's Cangrelor - Analyst Blog
1/10/2013, 11:40 am from Zacks.com in Investing, Business, Stocks
The Medicines Company ( MDCO ) recently
received good news with the company announcing positive results on
its phase III candidate, cangrelor. Cangrelor is being developed
for the... Read >>
Optimer's Dificid Sales Look Good - Analyst Blog
1/9/2013, 6:25 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals Inc. ( OPTR ) recently
announced its preliminary sales for the fourth quarter and full
year 2012. Optimer said that preliminary gross product sales of its... Read >>
Abbott's ABSORB in Phase III Trial - Analyst Blog
1/9/2013, 5:51 pm from Zacks.com in Investing, Business, Stocks
Abbott Laboratories ( ABT ) recently
announced that its Absorb Bioresorbable Vascular Scaffold (BVS)
device has moved into a phase III study, ABSORB III, in the US. The randomized,... Read >>
Repligen, Pfizer Collaborate - Analyst Blog
1/8/2013, 6:40 pm from Zacks.com in Investing, Business, Stocks
Repligen Corporation ( RGEN )
recently joined forces with Pfizer, Inc. ( PFE )
for the advancement of its spinal muscular atrophy (SMA)
program. The Candidate
The SMA program was... Read >>
Aegerion Upbeat About 2013 - Analyst Blog
1/8/2013, 6:15 pm from Zacks.com in Investing, Business, Stocks
Aegerion Pharmaceuticals Inc. ( AEGR )
recently announced its 2013 guidance as the company prepares for
the launch of Juxtapid, which gained US Food and Drug
Administration (FDA) approval... Read >>
Encouraging Prelim Results at DNDN - Analyst Blog
1/8/2013, 5:35 pm from Zacks.com in Investing, Business, Stocks
Dendreon Corporation ( DNDN )
recently announced preliminary results for the fourth quarter of
2012. Fourth quarter 2012 Preliminary Results Dendreon expects to generate net product... Read >>
Get Ready To Be Surprised This Earnings Season - Screen of the Week
1/8/2013, 3:19 am from Zacks.com in Investing, Earnings, Investing Ideas, Stocks
With earnings having just begun, this is a good screen to use
both before and after a company reports.
Like any earnings season, we're going to see both positive
surprises and negative... Read >>
AMAG Gives 4Q12 Snapshot - Analyst Blog
1/7/2013, 6:20 pm from Zacks.com in Investing, Business, Stocks
AMAG Pharmaceuticals ( AMAG )
recently announced its preliminary fourth quarter 2012 financial
results and its guidance for 2013. The company's total revenue for
2012 is expected to be... Read >>
BioMimetic's Pipeline Progresses - Analyst Blog
1/4/2013, 6:16 pm from Zacks.com in Investing, Business, Stocks
Biotechnology company, BioMimetic Therapeutics,
Inc. ( BMTI ) recently announced that it has started
enrolling patients for a phase II trial of its candidate, Augment
Chronic Tendinopathy... Read >>
Positive Data on Alkermes Candidate - Analyst Blog
1/4/2013, 8:49 am from Zacks.com in Investing, Business, Stocks
Alkermes plc ( ALKS )
recently announced positive results from a phase I study on its new
antipsychotic candidate, ALKS 3831. ALKS 3831 is a combination of
ALKS 33, and Eli Lilly and... Read >>
Coronado Amends Ovamed Agreement - Analyst Blog
1/3/2013, 6:30 pm from Zacks.com in Investing, Business, Stocks
Coronado Biosciences ( CNDO )
recently amended its existing license and supply agreements with
Ovamed GmbH. Coronado now has the manufacturing rights to its lead
product TSO (Trichuris suis... Read >>
Top Stocks with Big Potential Catch-Up Moves - Screen of the Week
1/2/2013, 12:12 am from Zacks.com in Investing, Investing Ideas, Stocks
Given the recent run-up in the market, here's a screen I've been
using recently for my own stock picking.
First, it focuses on the top Zacks Ranked Sectors and Industries.
Then it focuses on... Read >>
Dendreon Sells Manufacturing Unit - Analyst Blog
12/27/2012, 4:00 pm from Zacks.com in Investing, Business, Stocks
Dendreon Corporation ( DNDN )
recently sold its immunotherapy manufacturing facility (IMF) to
Novartis Pharmaceuticals Corporation ( NVS )
for $43 million in cash. The manufacturing... Read >>